https://www.selleckchem.com/products/tph104m.html
3 ± 5.6 years, range 65-89) were enrolled. Of 63 subjects, 23 (36.5%) had an "early complete response" profile, which means the achievement of a UAS7 score of "0" within the first 7 days of therapy. The most frequent comorbidity was hypertension, which affected 26 of 63 (41.3%) patients; no adverse events were reported. No significant correlations were found between treatment effectiveness and comorbidities. Omalizumab is a safe and effective therapy also in elderly patients with multiple comorbidities.Jarisch-Herxheimer reaction (JHR)
Gefällt mir
Kommentar
Teilen
